SAB Biotherapeutics, Inc.
SABSW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $10.5K in total; no superinvestor holds it.
Other share classesSABS
Q4 2023 vs. Q3 2023
How the institutions holding SAB Biotherapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 9 | 10 | +1 |
| Shares | 1.32M | 1.26M | −55.0K (−4.2%) |
| Value | $93.0K | $38.1K | −$55.0K (−59.1%) |
New holders (1)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 29,080 | $872 | 0.00% |
Sold out (0)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
None.